
Journal of Medicinal Chemistry p. 604 - 608 (1989)
Update date:2022-07-30
Topics:
Thurston
Imakura
Haruna
Li
Liu
Liu
Cheng
Lee
A principal mechanism of action of the clinical antitumor drugs etoposide (1) and teniposide (2) is the inhibition of catalytic activity of type II DNA topoisomerase and concurrent enzyme-mediated production of lethal DNA strand breaks. Substitution of the glycosidic moiety of 1 or 2 by ester and ethers, as well as the esterification and etherification of α-peltatin (4) including its glucosidic ethylidene and thenylidene cyclic acetals (25 and 26), has afforded compounds of much less activity than that of 1. The in vitro cytotoxicity (KB) appears to have no correlation with the inhibitory activity of the human DNA topoisomerase II.
View MoreContact:+1-973-357-0577
Address:10 Taft Rd.
Yingkou Sanzheng New Technology Chemical Industry Co., Ltd.
Contact:+86-417-2927806
Address:yingkou
Contact:18669908765
Address:Zibo City, Shandong Province, P.R.China
JinTan Pingsheng Chemical Co.,Ltd
Contact:+86-519-82828200
Address:NO.11Danfengxilu Road,Jintan City,Jiangsu,China
Contact:13813902930 025-52714267
Address:20 Fengji Road, Yuhua Economic Development Zone, Nanjing, Jiangsu, P. R. China
Doi:10.1021/jo01091a039
(1959)Doi:10.1021/ja01564a058
(1957)Doi:10.1007/BF03251529
(1956)Doi:10.1039/c39950001139
(1995)Doi:10.1016/j.bmc.2008.01.018
(2008)Doi:10.1021/ol301916t
(2012)